The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Mesenchymal Stromal Cells and Their Extracellular Vesicles Enhance the Anti-Inflammatory Phenotype of Regulatory Macrophages by Downregulating the Production of Interleukin (IL)-23 and IL-22
Open accessAbstract
Resolution-phase macrophage population orchestrates active dampening of the inflammation by secreting anti-inflammatory and proresolving products including interleukin (IL)-10 and lipid mediators. We investigated the effects of both human bone marrow-derived mesenchymal stromal cells (MSCs) and MSC-derived extracellular vesicles (MSC-EVs) on mature human regulatory macrophages (Mregs). The cytokines and lipid mediators were determined from cell culture media of Mregs cultivated with MSCs and MSC-EVs. Additionally, the alterations in the expression of cell surface markers and the phagocytic ability of Mregs were investigated. Our novel findings indicate that both MSC co-culture and MSC-EVs down-regulated the production of IL-23 and IL-22 enhancing the anti-inflammatory phenotype of Mregs and amplifying proresolving properties. The levels of prostaglandin E2 (PGE2) were substantially upregulated in MSC co-culture media, which may endorse proresolving lipid mediator class switching. Additionally, our results manifest, for the first time, that MSC-EVs mediate the Mreg phenotype change via PGE2. These data suggest that both human MSC and MSC-EVs may potentiate tolerance-promoting proresolving phenotype of human Mregs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The authors also demonstrated that MSC-EVs mediate their action, at least in part, via PGE2 (Table 1) [75].”
From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [75]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Hyvarinen and co-workers have shown that BM-MSCs co-culture with regulatory macrophages and MSC-EVs decrease the levels of IL-22 and IL-23 in the macrophages-produced CM [75].”
From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Macrophages in Tissue Repair, Regeneration, and Fibrosis
Wynn, T. A., & Vannella, K. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.015 · Cited by 4,481
Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1112 · Cited by 3,166 · cited 2×
“Kalim KW, Groettrup M. Prostaglandin E2 inhibits IL-23 and IL-12 production by human monocytes through down-regulation of their common p40 subunit.”
BackgroundMurray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981
Németh, K., Leelahavanichkul, A., Yuen, P. S. T., Mayer, B., Parmelee, A., Doi, K., Robey, P. G., Leelahavanichkul, K., Koller, B. H., Brown, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1905 · Cited by 2,364
Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury
Lai, R. C., Arslan, F., Lee, M. M., Sze, N. S. K., Choo, A., Chen, T. S., Salto-Tellez, M., Timmers, L., Lee, C. N., El Oakley, R. M., et al. (2010) · Stem Cell Research · doi:10.1016/j.scr.2009.12.003 · Cited by 2,215
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P. A., Kasman, I. M., Eastham‐Anderson, J., Wu, J., & Ouyang, W. (2006) · Nature · doi:10.1038/nature05505 · Cited by 1,888
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–114 of 114
A Computational Fluid Dynamics study of scaffolds under perfusion flow
Chinchilla-Mendez, J. A. (2022) · Queensland University of Technology · doi:10.5204/thesis.eprints.231384
CURRENT STATUS AND FUTURE PROSPECTS OF STEM CELL THERAPY IN ANIMAL HEALTH
(2022) · International Journal of Veterinary Science · doi:10.47278/book.ahp/2022.25
Mesenchymal stem cells: application in chronic lung disease
Adamič, N. (2023) · UK-Vet Equine · doi:10.12968/ukve.2023.7.6.218
Amaro-Prellezo, E. (2024) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/202973
Gorji, A. V., Fakhredini, F., Soltanpour, F., & Mansouri, E. (2025) · Advanced Biomedical Research · doi:10.4103/abr.abr_338_24
Craniomaxillofacial-Derived MSCs in Congenital Defect Reconstruction
Song, X., Peng, L., Bian, Z., & Yin, W. (2025) · Biomolecules · doi:10.3390/biom15070953
Amaro-Prellezo, E., Gómez-Ferrer, M., Hakobyan, L., Ontoria‐Oviedo, I., Peiró-Molina, E., Tarazona, S., Salguero, P., Ruiz‐Saurí, A., Selva-Roldán, M., Vives-Sánchez, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26726549
Amaro-Prellezo, E., Gómez-Ferrer, M., Hakobyan, L., Ontoria‐Oviedo, I., Peiró-Molina, E., Tarazona, S., Salguero, P., Ruiz‐Saurí, A., Selva-Roldán, M., Vives-Sánchez, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26726537
Amaro-Prellezo, E., Gómez-Ferrer, M., Hakobyan, L., Ontoria‐Oviedo, I., Peiró-Molina, E., Tarazona, S., Salguero, P., Ruiz‐Saurí, A., Selva-Roldán, M., Vives-Sánchez, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26726543
Amaro-Prellezo, E., Gómez-Ferrer, M., Hakobyan, L., Ontoria‐Oviedo, I., Peiró-Molina, E., Tarazona, S., Salguero, P., Ruiz‐Saurí, A., Selva-Roldán, M., Vives-Sánchez, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26726546
Amaro-Prellezo, E., Gómez-Ferrer, M., Hakobyan, L., Ontoria‐Oviedo, I., Peiró-Molina, E., Tarazona, S., Salguero, P., Ruiz‐Saurí, A., Selva-Roldán, M., Vives-Sánchez, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26726534
Amaro-Prellezo, E., Gómez-Ferrer, M., Hakobyan, L., Ontoria‐Oviedo, I., Peiró-Molina, E., Tarazona, S., Salguero, P., Ruiz‐Saurí, A., Selva-Roldán, M., Vives-Sánchez, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26726540
Raza, A., Wang, P., Liu, F., Arshad, S., Asim, M. H., Yang, Z., & Cai, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1860228
Yasutake, T., Tano, K., Oya, S., Oka, A., Tsukahara‐Kawamura, T., & Hirayama, M. (2026) · Biologics · doi:10.3390/biologics6040028
Metadata
- Authors
- Hyvärinen, K., Holopainen, M., Skirdenko, V., Ruhanen, H., Lehenkari, P., Korhonen, M., Käkelä, R., Laitinen, S., & Kerkelä, E.
- Affiliations
- Finnish Red Cross (FI)
- University of Helsinki (FI)
- Oulu University Hospital (FI)
- Corresponding author
- Hyvärinen, Kati
- ORCID
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-04-12
- Volume
- 9
- Pages
- 771-771
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC5906545
- OpenAlex
- W2797721539
- Cited by
- 111
- References
- 58
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 17 · 2023: 19 · 2022: 17 · 2021: 17 · 2020: 20 · 2019: 4 · 2018: 5
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Työväentutkimus Vuosikirja (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Tekes (3986/31/2013)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- mesenchymal stem cells, extracellular vesicles, regulatory macrophages, IL-23, IL-22, prostaglandin E2, inflammation resolution, specialized pro-resolving mediators, phagocytosis, cell surface markers, bone marrow-derived cells
- MeSH terms
- Extracellular Vesicles, Interleukin-22, Humans, Immune Tolerance, Inflammation, Interleukins, Macrophages, Phenotype, Down-Regulation, Interleukin-23, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
